news, Northwind Pharmaceuticals

Northwind Names Betsy Bigler as COO

SEPTEMBER 2018 – Northwind Pharmaceuticals is excited to announce the promotion of Elizabeth “Betsy” Bigler to Chief Operating Officer. Bigler joined Northwind from Community Health Network late in 2017, where she served as Director of Maternity Services. A 2008 graduate from the Purdue School of Nursing, Bigler obtained her Master’s degree from the University of Indianapolis in 2013 and her Six Sigma Blackbelt Certification in 2016. Bigler has made significant contributions to all aspects of Northwind’s business over the last 8 months in her role as VP, Quality and Administration. As COO, Bigler will be responsible for all operations within Northwind Pharmaceuticals and its sister company, Crosswind Pharmacy.

“Rapid growth over the last 18 months demands that we continue to build-out our leadership infrastructure and I am thrilled to see Betsy step up to this role,” said Phillip Berry, CEO. “Betsy’s process improvement expertise, employee development skills, and organizational leadership capabilities will be critical in helping Northwind and Crosswind scale in the coming months.”

Northwind provides diverse pharmaceutical repackaging, fulfillment, and support services to patients, medical providers, and employer groups nationally. Founded in 2008 and based in Indianapolis, Northwind enables medical providers to get prescription drugs to their patients in the clinic, at home, at work, and in care facilities. With a particular focus on self-funded employer groups, Northwind provides money-saving drug management and delivery solutions through worksite clinics serving employees.

Crosswind Pharmacy is a wholesale home delivery pharmacy specializing in serving self-funded employers and their employees. Founded in 2016, Crosswind has grown rapidly to become a premier provider of cost-effective, contract pharmacy and micro-PBM services to employers through onsite and nearsite clinics.

Schedule a free claims analysis now.

Let’s Talk now

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading

Letter From a Pharmacist – On Pharmacy Closures

Phillip Berry | Oct 25th, 2024
Pharmacists have a time-honored role as an integral contributor to the delivery of health care. From the earliest apothecaries to the retail stores of today, community pharmacists have provided guidance about health, wellness and medication therapy. Their expertise ranges from preventive care to the most advanced medications used in the treatment of complex disease.  Despite … more »

continue reading

Stewardship and the Beauty of Health Benefits

Phillip Berry | Oct 25th, 2024
The Beauty of Making a Difference Beauty in health benefits? What does that even mean? Think back on your experience as an HR/benefits professional. What are the peak moments? Most would agree that the high points are moments when they see their work directly impacting an employee or plan member. A time when the health … more »

continue reading